The study exploited a deceptively simple but powerful model system, the budding yeast Saccharomyces cerevisiae. The researchers worked with 354 inbred yeast strains originally developed in a previous effort, a cohort that collectively carries roughly 12,000 single-nucleotide polymorphisms distributed across all yeast chromosomes and even the mitochondrial genome. Because the strains are inbred, their alleles segregate in an approximately 50:50 pattern, which gives the mapping approach clean statistical footing. Crucially, this kind of population has long been a workhorse for classical quantitative trait loci studies, but the Montreal team asked a question that had rarely been posed at this scale: rather than measuring visible traits or mRNA levels, could they measure the strength of protein–protein interactions themselves as quantitative traits, and then trace those measurements back to specific DNA variants?

To answer that question, the group deployed a protein-fragment complementation assay built on murine dihydrofolate reductase, or DHFR. The strategy works like a molecular switch. Each of two interacting partner proteins is fused to a complementary fragment of the DHFR enzyme. When the two proteins come together in the living cell, the fragments reconstitute a functional enzyme that confers resistance to the drug methotrexate. Growth under drug pressure therefore becomes a quantitative, high-throughput readout of interaction strength: the more strongly two proteins associate, the better the cells survive. The researchers engineered 61 such reporter pairs, tagging the relevant genes directly in the chromosomes of every strain using a streamlined CRISPR/Cas9 and homologous recombination workflow, and gave each strain a unique DNA barcode so that all 354 genomes could be pooled and sequenced together in a single competitive growth assay.

The results, presented across a series of Manhattan plots and quantitative maps, revealed a rich landscape the authors call the genetic architecture of protein–protein interactions, summarized in a new class of loci they named piQTLs, protein-interaction quantitative trait loci. Across 61 reporter pairs and five growth conditions, the team identified roughly 1,180 lead variants, about four per reporter pair per condition, corresponding to 354 unique SNPs spread over 282 distinct gene loci. The single most striking pattern concerned the split between cis- and trans-acting effects. Variants acting in cis, meaning they sit near the genes encoding the interacting pair itself, were rare. Variants acting in trans, located anywhere else in the genome and often on entirely different chromosomes, dominated the landscape and carried noticeably stronger per-variant effect sizes. In this respect, the regulation of protein interactions echoes a theme well established for gene expression, where trans effects are numerous and diffuse, but the interaction layer adds its own architectural twist.

That twist emerged when the researchers looked at where trans-piQTLs fall in the yeast protein interaction network. Consistent with the small-world architecture that characterizes protein networks, variants influencing a given reporter interaction tended to map to genes encoding proteins that sit close to that reporter pair in the network, even when the variants were far away in genomic space. The team formalized this observation through large-scale simulations, randomly drawing comparable sets of genes 10,000 times and asking how often they would fall as near to a reporter pair as the real piQTLs did. The answer was clear: the observed proximity was not a product of chance. This network-proximity principle is more than a statistical curiosity. It suggests that the web of interactions inside a cell channels the downstream effects of genetic variation, meaning that perturbations propagate along local neighborhoods of the interactome rather than scattering randomly, a property that could be exploited to prioritize candidate causal genes in human disease studies.

Perhaps the most provocative findings came from the poorly annotated corners of the yeast genome. The researchers identified and experimentally validated piQTLs in noncoding RNAs, including the Xrn1-sensitive antisense transcripts known as XUTs, as well as in 3′ untranslated regions, and these regulatory variants carried effect sizes comparable to those of variants landing squarely inside protein-coding sequences. In other words, DNA that does not code for protein can still measurably tune how two proteins grip each other in vivo. This finding expands the functional repertoire of noncoding variation and hints that some of the so-called missing heritability of complex human traits, the gap between known genetic associations and explained disease risk, may hide not only in unannotated regulatory DNA but in its consequences for the physical wiring of the proteome.

The study also delivered an instructive comparison with two other molecular QTL disciplines, expression QTLs that track mRNA abundance and protein abundance QTLs that track protein levels. When the team overlapped their piQTLs with results from highly powered yeast linkage studies, including an eQTL analysis of 942 diverse isolates and a pQTL analysis of 1,086 near telomere-to-telomere genomes, a telling asymmetry appeared: piQTLs overlapped more with pQTLs than with eQTLs, even after rigorous size-matched permutation testing. The interpretation is that protein interactions sit downstream of transcription and closer to the proteome-level machinery of the cell, capturing post-transcriptional regulation, protein abundance effects and molecular assembly processes that RNA measurements simply cannot see. Some variants alter how much of a protein is made; others change what that protein does once made, and the interactome assay registers both.

The practical payoff of the approach became visible when the researchers grew their pooled strains under drug treatment. In experiments with methotrexate, fluconazole, 5-fluorocytosine, metformin and trifluoperazine, drug-specific piQTLs emerged that traced the mechanism of action of each compound through the interaction network. Fluconazole, an antifungal that targets the Erg11 enzyme of the ergosterol pathway, produced piQTLs concentrated in genes linked to that pathway, including variants inside the Erg11 coding sequence itself. Metformin, the widely used diabetes drug, revealed interaction changes in mitochondrial and metabolic proteins that align with known aspects of its biology. This capacity to read a drug’s fingerprint directly off the interactome suggests that piQTL mapping could become a genuine screening tool, one that identifies variants modulating drug response and flags off-target mechanisms that conventional growth assays might miss entirely.

All of the raw sequencing data, computational code and mapping results have been released openly, with raw reads deposited in the Gene Expression Omnibus, analysis pipelines on GitHub, and an interactive web server that lets any visitor browse the Manhattan plots, quantile–quantile diagnostics and a genome browser annotated with noncoding RNA features. The authors acknowledge clear limitations, including the modest number of reporter interactions surveyed relative to the thousands of interactions known in yeast and the statistical power constraints of a 354-strain cohort, which can only detect effect sizes of roughly 0.06 or larger. Yet the conceptual advance is hard to overstate. By demonstrating that the strength of protein–protein interactions behaves as an ordinary quantitative trait that can be mapped across a genome, the study opens a third major molecular dimension for genetics, beyond transcript and protein abundance, and points toward a future in which the interpretive power of human genome-wide association studies is amplified by the connective tissue of the cell, the interaction networks where biology actually happens.

Subject of Research: Mapping how natural genetic variation alters in vivo protein–protein interaction strength in budding yeast.

Article Title: Genetic landscape of an in vivo protein interactome

Article References: Genetic landscape of an in vivo protein interactome. (n.d.). https://doi.org/10.1038/s41588-026-02747-z

Image Credits: AI Generated

DOI: 10.1038/s41588-026-02747-z

Keywords: protein–protein interactions, piQTL, yeast genetics, quantitative trait loci, noncoding RNAs, GWAS, missing heritability, proteome, CRISPR, drug mechanisms, interaction networks, functional genomics